La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Auddia a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Auddia..

Auddia (NASDAQ:AUUD) Azioni, Catena delle Opzioni

Auddia

Auddia Inc is a technology company that is engaged in radio broadcasts and streaming audio content digitally. Its products includes Auddia App which is a subscription-based commercial-free AM/FM software application, and Vodacast an interactive podcasting platform and application. The company generates revenue through subscription fees from customers accessing the company's cloud-based computing services and advertisement services.

Auddia Inc

News

NVDA

ServiceNow And NVIDIA Announce Expansion Of Partnership To Fuel New Class Of Intelligent AI Agents Across The Enterprise

<p>Keefe, Bruyette &amp; Woods  analyst Meyer Shields   maintains Axis Capital Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AXS#NYSE">AXS</a>) with a Outperform and raises the price target from $114 to $118.</p>


Price Target

Analyst Ratings

Keefe, Bruyette & Woods Maintains Outperform on Axis Capital Holdings, Raises Price Target to $118

<h3>Gainers</h3>
<ul>
<li><strong>ThredUp</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TDUP#NASDAQ">TDUP</a>) shares moved upwards by 41.3% to $6.28 during Tuesday's regular session. The company's market cap stands at $713.8 million. As per the news, the Q1 earnings report came out yesterday. </li>
<li><strong>EVgo</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVGO#NASDAQ">EVGO</a>) stock moved upwards by 31.22% to $3.63. The company's market cap stands at $475.0 million. As per the news, the Q1 earnings report came out today. </li>
<li><strong>NWTN</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NWTN#NASDAQ">NWTN</a>) stock rose 29.99% to $0.49. The market value of their outstanding shares is at $141.5 million. </li>
<li><strong>WeRide</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WRD#NASDAQ">WRD</a>) stock rose 22.84% to $8.41. The company's market cap stands at $2.3 billion. </li>
<li><strong>Lobo EV Technologies</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LOBO#NASDAQ">LOBO</a>) shares moved upwards by 19.59% to $0.8. The company's market cap stands at $6.8 million. </li>
<li><strong>Top Win International</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TOPW#NASDAQ">TOPW</a>) shares increased by 18.77% to $3.55. The company's market cap stands at $88.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li><strong>Raytech Holding</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RAY#NASDAQ">RAY</a>) shares fell 30.4% to $1.03 during Tuesday's regular session. The market value of their outstanding shares is at $18.1 million. </li>
<li><strong>Jeffs Brands</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JFBR#NASDAQ">JFBR</a>) shares declined by 26.21% to $0.98. The market value of their outstanding shares is at $1.8 million. </li>
<li><strong>First Watch Restaurant Gr</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FWRG#NASDAQ">FWRG</a>) stock decreased by 24.24% to $14.1. The market value of their outstanding shares is at $855.8 million. As per the press release, Q1 earnings came out today. </li>
<li><strong>LiveWire Gr</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LVWR#NYSE">LVWR</a>) stock fell 14.29% to $1.14. The market value of their outstanding shares is at $231.9 million. As per the news, the Q1 earnings report came out 3 days ago. </li>
<li><strong>Color Star Tech</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADD#NASDAQ">ADD</a>) stock decreased by 13.95% to $0.86. </li>
<li><strong>U Power</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UCAR#NASDAQ">UCAR</a>) shares declined by 12.69% to $2.96. The company's market cap stands at $12.5 million.<br />
<strong>See Also:</strong> <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Movers

EVGO

FWRG

JFBR

LOBO

LVWR

NWTN

TDUP

TOPW

UCAR

12 Consumer Discretionary Stocks Moving In Tuesday's Intraday Session

<h3>Gainers</h3>
<ul>
<li><strong>Regencell Bioscience</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) shares rose 125.8% to $209.7 during Tuesday's regular session. The market value of their outstanding shares is at $2.7 billion. </li>
<li><strong>China SXT Pharmaceuticals</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SXTC#NASDAQ">SXTC</a>) shares increased by 32.66% to $1.87. The company's market cap stands at $25.7 million. </li>
<li><strong>Tiziana Life Sciences</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLSA#NASDAQ">TLSA</a>) shares moved upwards by 28.27% to $1.56. The company's market cap stands at $182.8 million. </li>
<li><strong>CareCloud</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCLD#NASDAQ">CCLD</a>) stock moved upwards by 26.68% to $2.22. The company's market cap stands at $93.8 million. The company's, Q1 earnings came out today. </li>
<li><strong>Cyclacel Pharmaceuticals</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>) stock moved upwards by 20.02% to $0.36. The market value of their outstanding shares is at $4.9 million. </li>
<li><strong>AquaBounty Techs</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AQB#NASDAQ">AQB</a>) stock increased by 18.37% to $0.76. The market value of their outstanding shares is at $2.9 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li><strong>NuCana</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCNA#NASDAQ">NCNA</a>) stock declined by 67.2% to $0.36 during Tuesday's regular session. The market value of their outstanding shares is at $2.1 million. </li>
<li><strong>bioAffinity Technologies</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIAF#NASDAQ">BIAF</a>) stock fell 44.74% to $0.21. The company's market cap stands at $3.8 million. </li>
<li><strong>Tactile Systems Tech</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCMD#NASDAQ">TCMD</a>) stock decreased by 31.53% to $9.54. The company's market cap stands at $225.8 million. The company's, Q1 earnings came out yesterday. </li>
<li><strong>Kodiak Sciences</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KOD#NASDAQ">KOD</a>) shares fell 21.24% to $3.88. The company's market cap stands at $204.4 million. </li>
<li><strong>Syndax Pharmaceuticals</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDX#NASDAQ">SNDX</a>) shares declined by 21.15% to $10.7. The company's market cap stands at $913.3 million. The company's, Q1 earnings came out yesterday. </li>
<li><strong>HealthStream</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSTM#NASDAQ">HSTM</a>) shares fell 18.75% to $27.01. The company's market cap stands at $824.4 million. As per the press release, Q1 earnings came out yesterday.<br />
<strong>See Also:</strong> <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


BIAF

CCLD

CYCC

HSTM

NCNA

SNDX

SXTC

TCMD

TLSA

12 Health Care Stocks Moving In Tuesday's Intraday Session

<h3>Gainers</h3>
<ul>
<li><strong>Babcock &amp; Wilcox Enterprises, Inc. 8.125% Senior Notes due 2026</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BWSN#NYSE">BWSN</a>) stock rose 44.9% to $11.65 during Tuesday's regular session. </li>
<li><strong>OneConstruction Group</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONEG#NASDAQ">ONEG</a>) stock moved upwards by 32.92% to $2.18. The company's market cap stands at $28.3 million. </li>
<li><strong>Advent Technologies Hldgs</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADN#NASDAQ">ADN</a>) stock moved upwards by 28.01% to $3.61. The market value of their outstanding shares is at $9.5 million. </li>
<li><strong>Babcock &amp; Wilcox Enterprises, Inc. 6.50% Senior Notes due 2026</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BWNB#NYSE">BWNB</a>) stock increased by 26.9% to $8.49. </li>
<li><strong>Rain Enhancement</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RAIN#NASDAQ">RAIN</a>) shares moved upwards by 24.7% to $4.77. The company's market cap stands at $36.1 million. </li>
<li><strong>High-Trend International</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTCO#NASDAQ">HTCO</a>) shares rose 22.21% to $1.65. The market value of their outstanding shares is at $199.5 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li><strong>Zoomcar Holdings</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZCAR#NASDAQ">ZCAR</a>) stock fell 35.7% to $6.65 during Tuesday's regular session. The company's market cap stands at $4.4 million. </li>
<li><strong>Hyperscale Data</strong> (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/GPUS#AMEX">GPUS</a>) stock declined by 35.57% to $4.99. The company's market cap stands at $7.6 million. </li>
<li><strong>JELD-WEN Holding</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JELD#NYSE">JELD</a>) stock fell 21.94% to $4.39. The company's market cap stands at $372.9 million. As per the press release, Q1 earnings came out yesterday. </li>
<li><strong>Willis Lease Finance</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WLFC#NASDAQ">WLFC</a>) shares decreased by 19.99% to $125.02. The market value of their outstanding shares is at $958.8 million. As per the news, the Q1 earnings report came out today. </li>
<li><strong>Energys Group</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENGS#NASDAQ">ENGS</a>) stock declined by 15.3% to $2.62. The company's market cap stands at $37.2 million. </li>
<li><strong>TrueBlue</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TBI#NYSE">TBI</a>) shares declined by 14.92% to $3.65. The company's market cap stands at $108.4 million. As per the press release, Q1 earnings came out yesterday.<br />
<strong>See Also:</strong> <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


BWNB

Babcock & Wilcox Enterprises, Inc. 8.125% Senior Notes due 2026

BWSN

ENGS

GPUS

HTCO

JELD

ONEG

RAIN

WLFC

ZCAR

12 Industrials Stocks Moving In Tuesday's Intraday Session

<h3>Gainers</h3>
<ul>
<li><strong>FOXO Technologies</strong> (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/FOXO#AMEX">FOXO</a>) stock rose 176.7% to $1.76 during Tuesday's regular session. The market value of their outstanding shares is at $6.3 million. </li>
<li><strong>Marin Software</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRIN#NASDAQ">MRIN</a>) stock rose 106.88% to $1.31. The market value of their outstanding shares is at $4.1 million. </li>
<li><strong>Pony AI</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PONY#NASDAQ">PONY</a>) shares rose 37.96% to $13.38. The company's market cap stands at $4.7 billion. </li>
<li><strong>Faro Technologies</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FARO#NASDAQ">FARO</a>) stock moved upwards by 34.51% to $42.3. The market value of their outstanding shares is at $813.3 million. </li>
<li><strong>CISO Global</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CISO#NASDAQ">CISO</a>) shares rose 28.8% to $0.74. The market value of their outstanding shares is at $10.7 million. </li>
<li><strong>Saiheat</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAIH#NASDAQ">SAIH</a>) stock rose 26.32% to $7.87. The market value of their outstanding shares is at $13.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li><strong>Ichor Holdings</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICHR#NASDAQ">ICHR</a>) stock fell 22.9% to $16.08 during Tuesday's regular session. The company's market cap stands at $546.7 million. The company's, Q1 earnings came out yesterday. </li>
<li><strong>DigitalOcean Holdings</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOCN#NYSE">DOCN</a>) shares declined by 14.57% to $27.99. The company's market cap stands at $2.5 billion. The company's, Q1 earnings came out today. </li>
<li><strong>Weave Communications</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WEAV#NYSE">WEAV</a>) shares fell 14.4% to $9.16. The company's market cap stands at $676.9 million. As per the news, the Q1 earnings report came out yesterday. </li>
<li><strong>Lattice Semiconductor</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSCC#NASDAQ">LSCC</a>) shares fell 13.62% to $45.32. The company's market cap stands at $6.2 billion. As per the press release, Q1 earnings came out yesterday. </li>
<li><strong>Palantir Technologies</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>) shares declined by 13.19% to $107.45. The market value of their outstanding shares is at $253.5 billion. As per the news, the Q1 earnings report came out yesterday. </li>
<li><strong>Turtle Beach</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TBCH#NASDAQ">TBCH</a>) stock fell 12.97% to $9.37. The market value of their outstanding shares is at $188.3 million.<br />
<strong>See Also:</strong> <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


CISO

DOCN

FARO

FOXO

ICHR

LSCC

MRIN

PLTR

PONY

SAIH

TBCH

WEAV

12 Information Technology Stocks Moving In Tuesday's Intraday Session

Macro Economic Events

Macro Notification

Econ #s

Economics

General

USA 10-Year Note Auction 4.342% Vs 4.435% Prior

<p>RGC Resources (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGCO#NASDAQ">RGCO</a>) is gearing up to announce its quarterly earnings on Wednesday, 2025-05-07. Here's a quick overview of what investors should know before the release.</p>
<p>Analysts are estimating that RGC Resources will report an <strong>earnings per share</strong> (EPS) of $0.68.</p>
<p>The market awaits RGC Resources's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.</p>
<p>It's important for new investors to understand that guidance can be a significant driver of stock prices.</p>
<h3>Past Earnings Performance</h3>
<p>During the last quarter, the company reported an EPS beat by $0.01, leading to a 0.28% drop in the share price on the subsequent day.</p>
<p>Here's a look at RGC Resources's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q1 2025</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.50</td>
<td>-0.01</td>
<td>0.07</td>
<td>0.65</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.51</td>
<td>0.01</td>
<td>0.02</td>
<td>0.63</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-0.0%</td>
<td>-2.0%</td>
<td>3.0%</td>
<td>1.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746551093_0.png" alt="eps graph" /></p>
<h3>RGC Resources Share Price Analysis</h3>
<p>Shares of RGC Resources were trading at $21.0 as of May 05. Over the last 52-week period, shares are up 3.06%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/RGCO/earnings"><strong>To track all earnings releases for RGC Resources visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Earnings

RGCO

Earnings Preview For RGC Resources

<p>Keefe, Bruyette &amp; Woods  analyst Jade Rahmani   maintains American Homes 4 Rent (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMH#NYSE">AMH</a>) with a Market Perform and raises the price target from $38 to $40.</p>


Keefe, Bruyette & Woods Maintains Market Perform on American Homes 4 Rent, Raises Price Target to $40

<p>MaxCyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MXCT#NASDAQ">MXCT</a>) will release its quarterly earnings report on Wednesday, 2025-05-07. Here's a brief overview for investors ahead of the announcement.</p>
<p>Analysts anticipate MaxCyte to report an <strong>earnings per share</strong> (EPS) of $-0.10.</p>
<p>Anticipation surrounds MaxCyte's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.</p>
<p>New investors should understand that while earnings performance is important, market reactions are often driven by guidance.</p>
<h3>Earnings Track Record</h3>
<p>Last quarter the company beat EPS by $0.02, which was followed by a 8.36% drop in the share price the next day.</p>
<p>Here's a look at MaxCyte's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.12</td>
<td>-0.12</td>
<td>-0.13</td>
<td>-0.13</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.10</td>
<td>-0.11</td>
<td>-0.09</td>
<td>-0.09</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-8.0%</td>
<td>-11.0%</td>
<td>-8.0%</td>
<td>18.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746551083_0.png" alt="eps graph" /></p>
<h3>Tracking MaxCyte's Stock Performance</h3>
<p>Shares of MaxCyte were trading at $2.67 as of May 05. Over the last 52-week period, shares are down 41.59%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release. </p>
<h3>Analyst Views on MaxCyte</h3>
<p>For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding MaxCyte.</p>
<p>Analysts have given MaxCyte a total of 1 ratings, with the consensus rating being Buy. The average one-year price target is $9.0, indicating a potential 237.08% upside.</p>
<h3>Peer Ratings Comparison</h3>
<p>This comparison focuses on the analyst ratings and average 1-year price targets of CryoPort, Maravai LifeSciences and Pacific Biosciences, three major players in the industry, shedding light on their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Buy trajectory for CryoPort, with an average 1-year price target of $10.8, suggesting a potential 304.49% upside.</li>
<li>Analysts currently favor an Neutral trajectory for Maravai LifeSciences, with an average 1-year price target of $4.62, suggesting a potential 73.03% upside.</li>
<li>Analysts currently favor an Outperform trajectory for Pacific Biosciences, with an average 1-year price target of $2.25, suggesting a potential 15.73% downside.</li>
</ul>
<h3>Analysis Summary for Peers</h3>
<p>The peer analysis summary presents essential metrics for CryoPort, Maravai LifeSciences and Pacific Biosciences, unveiling their respective standings within the industry and providing valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>MaxCyte</td>
<td>Buy</td>
<td>-44.51%</td>
<td>$6.41M</td>
<td>-5.05%</td>
</tr>
<tr>
<td>CryoPort</td>
<td>Buy</td>
<td>3.97%</td>
<td>$27.28M</td>
<td>-5.49%</td>
</tr>
<tr>
<td>Maravai LifeSciences</td>
<td>Neutral</td>
<td>-23.92%</td>
<td>$18.96M</td>
<td>-7.80%</td>
</tr>
<tr>
<td>Pacific Biosciences</td>
<td>Outperform</td>
<td>-32.79%</td>
<td>$10.06M</td>
<td>0.49%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>MaxCyte ranks at the bottom for Revenue Growth and Gross Profit among its peers. It is also at the bottom for Return on Equity. Overall, MaxCyte's performance is weaker compared to its peers in all key metrics analyzed.</p>
<h3>All You Need to Know About MaxCyte</h3>
<p>MaxCyte Inc is a commercial cell engineering company focused on providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support cell-based research and development. The company has developed and commercialized a proprietary Flow Electroporation platform, which facilitates the complex engineering of a wide variety of cells. The Company has one reportable segment, cell engineering technology. The revenue is generated from the sale and licensing of company's instruments, as well as sales of single-use disposable processing assemblies.</p>
<h3>Key Indicators: MaxCyte's Financial Health</h3>
<p><strong>Market Capitalization Analysis:</strong> The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.</p>
<p><strong>Decline in Revenue:</strong> Over the 3 months period, MaxCyte faced challenges, resulting in a decline of approximately <strong>-44.51%</strong> in revenue growth as of 31 December, 2024. This signifies a reduction in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>-121.9%,</strong> the company showcases strong profitability and effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> MaxCyte's ROE stands out, surpassing industry averages. With an impressive ROE of <strong>-5.05%</strong>, the company demonstrates effective use of equity capital and strong financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> MaxCyte's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of <strong>-4.34%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>0.09</strong>.</p>
<p><a href="https://www.benzinga.com/quote/MXCT/earnings"><strong>To track all earnings releases for MaxCyte visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


MXCT

A Look at MaxCyte's Upcoming Earnings Report

<p>Valneva (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VALN#NASDAQ">VALN</a>) will release its quarterly earnings report on Wednesday, 2025-05-07. Here's a brief overview for investors ahead of the announcement.</p>
<p>Analysts anticipate Valneva to report an <strong>earnings per share</strong> (EPS) of $-0.20.</p>
<p>Anticipation surrounds Valneva's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.</p>
<p>New investors should understand that while earnings performance is important, market reactions are often driven by guidance.</p>
<h3>Past Earnings Performance</h3>
<p>The company's EPS missed by $0.32 in the last quarter, leading to a 1.1% drop in the share price on the following day.</p>
<p>Here's a look at Valneva's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.22</td>
<td>-0.29</td>
<td>-0.30</td>
<td>0.94</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.54</td>
<td>-0.15</td>
<td>-0.37</td>
<td>0.89</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-1.0%</td>
<td>-4.0%</td>
<td>5.0%</td>
<td>-3.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746551057_0.png" alt="eps graph" /></p>
<h3>Stock Performance</h3>
<p>Shares of Valneva were trading at $6.6562 as of May 05. Over the last 52-week period, shares are down 10.08%.  Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/VALN/earnings"><strong>To track all earnings releases for Valneva visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


VALN

Insights Ahead: Valneva's Quarterly Earnings

<p>Liberty Latin America (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LILAK#NASDAQ">LILAK</a>) is gearing up to announce its quarterly earnings on Wednesday, 2025-05-07. Here's a quick overview of what investors should know before the release.</p>
<p>Analysts are estimating that Liberty Latin America will report an <strong>earnings per share</strong> (EPS) of $-0.12.</p>
<p>The announcement from Liberty Latin America is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.</p>
<p>It's worth noting for new investors that guidance can be a key determinant of stock price movements.</p>
<h3>Past Earnings Performance</h3>
<p>During the last quarter, the company reported an EPS missed by $0.90, leading to a 5.17% drop in the share price on the subsequent day.</p>
<p>Here's a look at Liberty Latin America's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0</td>
<td>-0.02</td>
<td>-0.08</td>
<td>-0.23</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.9</td>
<td>-2.22</td>
<td>-0.22</td>
<td>0</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-5.0%</td>
<td>-21.0%</td>
<td>-9.0%</td>
<td>5.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746551043_0.png" alt="eps graph" /></p>
<h3>Market Performance of Liberty Latin America's Stock</h3>
<p>Shares of Liberty Latin America were trading at $5.3 as of May 05. Over the last 52-week period, shares are down 37.44%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/LILAK/earnings"><strong>To track all earnings releases for Liberty Latin America visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


LILAK

An Overview of Liberty Latin America's Earnings

<p>DXP Enterprises (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXPE#NASDAQ">DXPE</a>) is preparing to release its quarterly earnings on Wednesday, 2025-05-07. Here's a brief overview of what investors should keep in mind before the announcement.</p>
<p>Analysts expect DXP Enterprises to report an <strong>earnings per share</strong> (EPS) of $1.20.</p>
<p>The market awaits DXP Enterprises's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.</p>
<p>It's important for new investors to understand that guidance can be a significant driver of stock prices.</p>
<h3>Overview of Past Earnings</h3>
<p>The company's EPS beat by $0.49 in the last quarter, leading to a 0.31% increase in the share price on the following day.</p>
<p>Here's a look at DXP Enterprises's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.89</td>
<td>0.95</td>
<td>0.80</td>
<td>0.71</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>1.38</td>
<td>1.43</td>
<td>1.02</td>
<td>0.74</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>0.0%</td>
<td>21.0%</td>
<td>-4.0%</td>
<td>-8.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746551019_0.png" alt="eps graph" /></p>
<h3>Tracking DXP Enterprises's Stock Performance</h3>
<p>Shares of DXP Enterprises were trading at $91.29 as of May 05. Over the last 52-week period, shares are up 64.65%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<h3>Analyst Observations about DXP Enterprises</h3>
<p>For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding DXP Enterprises.</p>
<p>The consensus rating for DXP Enterprises is Outperform, derived from 1 analyst ratings. An average one-year price target of $95.0 implies a potential 4.06% upside.</p>
<h3>Understanding Analyst Ratings Among Peers</h3>
<p>In this analysis, we delve into the analyst ratings and average 1-year price targets of Xometry, Distribution Solns Gr and Dnow, three key industry players, offering insights into their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Outperform trajectory for Xometry, with an average 1-year price target of $33.71, suggesting a potential 63.07% downside.</li>
<li>Analysts currently favor an Outperform trajectory for Distribution Solns Gr, with an average 1-year price target of $44.0, suggesting a potential 51.8% downside.</li>
<li>Analysts currently favor an Buy trajectory for Dnow, with an average 1-year price target of $19.0, suggesting a potential 79.19% downside.</li>
</ul>
<h3>Comprehensive Peer Analysis Summary</h3>
<p>In the peer analysis summary, key metrics for Xometry, Distribution Solns Gr and Dnow are highlighted, providing an understanding of their respective standings within the industry and offering insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>DXP Enterprises</td>
<td>Outperform</td>
<td>15.69%</td>
<td>$148.49M</td>
<td>5.17%</td>
</tr>
<tr>
<td>Xometry</td>
<td>Outperform</td>
<td>15.92%</td>
<td>$59.02M</td>
<td>-3.14%</td>
</tr>
<tr>
<td>Distribution Solns Gr</td>
<td>Outperform</td>
<td>14.89%</td>
<td>$163.98M</td>
<td>0.51%</td>
</tr>
<tr>
<td>Dnow</td>
<td>Buy</td>
<td>2.88%</td>
<td>$133M</td>
<td>2.06%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>DXP Enterprises ranks at the top for Revenue Growth among its peers. It is in the middle for Gross Profit. For Return on Equity, DXP Enterprises is at the bottom compared to its peers.</p>
<h3>All You Need to Know About DXP Enterprises</h3>
<p>DXP Enterprises Inc is a distributor of products and services to industrial customers in the United States, Canada, Mexico, and Dubai. The company's reportable segments include Service Centers, Innovative Pumping Solutions, and Supply Chain Services. It generates maximum revenue from the Service Centers segment. The company offers pumping solutions, supply chain services and maintenance, repair, operating, and production services for rotating equipment, bearings, power transmissions, industrial supplies, and safety products. It serves the General Industrial, Oil &amp; Gas, Food &amp; Beverage, Water &amp; Wastewater, Chemical, Transportation, Aerospace &amp; Others.</p>
<h3>DXP Enterprises: Financial Performance Dissected</h3>
<p><strong>Market Capitalization Analysis:</strong> Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> DXP Enterprises's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately <strong>15.69%</strong>. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Industrials sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>4.53%,</strong> the company showcases strong profitability and effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> DXP Enterprises's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of <strong>5.17%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of <strong>1.65%,</strong> the company showcases effective utilization of assets.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>1.6</strong>, DXP Enterprises adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<p><a href="https://www.benzinga.com/quote/DXPE/earnings"><strong>To track all earnings releases for DXP Enterprises visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


DXPE

A Glimpse of DXP Enterprises's Earnings Potential

<p>Navios Maritime Partners (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NMM#NYSE">NMM</a>) is gearing up to announce its quarterly earnings on Wednesday, 2025-05-07. Here's a quick overview of what investors should know before the release.</p>
<p>Analysts are estimating that Navios Maritime Partners will report an <strong>earnings per share</strong> (EPS) of $2.84.</p>
<p>Investors in Navios Maritime Partners are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.</p>
<p>It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.</p>
<h3>Earnings History Snapshot</h3>
<p>Last quarter the company missed EPS by $0.46, which was followed by a 0.18% increase in the share price the next day.</p>
<p>Here's a look at Navios Maritime Partners's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>3.07</td>
<td>3.99</td>
<td>2.84</td>
<td>2</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>2.61</td>
<td>3.15</td>
<td>3.06</td>
<td>2.32</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>0.0%</td>
<td>-1.0%</td>
<td>-2.0%</td>
<td>-1.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746551010_0.png" alt="eps graph" /></p>
<h3>Market Performance of Navios Maritime Partners's Stock</h3>
<p>Shares of Navios Maritime Partners were trading at $36.37 as of May 05. Over the last 52-week period, shares are down 21.95%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/NMM/earnings"><strong>To track all earnings releases for Navios Maritime Partners visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


A Look Ahead: Navios Maritime Partners's Earnings Forecast

<p><strong>Sprott</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SII#NYSE">SII</a>) is set to give its latest quarterly earnings report on Wednesday, 2025-05-07. Here's what investors need to know before the announcement.</p>
<p>Analysts estimate that Sprott will report an <strong>earnings per share</strong> (EPS) of $0.46. </p>
<p>Sprott bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Earnings History Snapshot</h3>
<p>Last quarter the company missed EPS by $0.02, which was followed by a 3.36% drop in the share price the next day.</p>
<p>Here's a look at Sprott's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.48</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.46</td>
<td>0.5</td>
<td>0.53</td>
<td>0.45</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-3.0%</td>
<td>1.0%</td>
<td>2.0%</td>
<td>3.0%</td>
</tr>
</tbody>
</table>
</p>
<h3>Tracking Sprott's Stock Performance</h3>
<p>Shares of Sprott were trading at $52.04 as of May 05. Over the last 52-week period, shares are up 31.68%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/SII/earnings"><strong>To track all earnings releases for Sprott visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


What's Next: Sprott's Earnings Preview

<p>Keefe, Bruyette &amp; Woods  analyst Meyer Shields   maintains Arch Capital Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACGL#NASDAQ">ACGL</a>) with a Outperform and raises the price target from $104 to $113.</p>


ACGL

Keefe, Bruyette & Woods Maintains Outperform on Arch Capital Group, Raises Price Target to $113

<p>Liberty Latin America (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LILA#NASDAQ">LILA</a>) is gearing up to announce its quarterly earnings on Wednesday, 2025-05-07. Here's a quick overview of what investors should know before the release.</p>
<p>Analysts are estimating that Liberty Latin America will report an <strong>earnings per share</strong> (EPS) of $-0.12.</p>
<p>Liberty Latin America bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Earnings History Snapshot</h3>
<p>Last quarter the company missed EPS by $0.96, which was followed by a 5.27% drop in the share price the next day.</p>
<p>Here's a look at Liberty Latin America's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.06</td>
<td>0.02</td>
<td>0</td>
<td>-0.14</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.90</td>
<td>-2.22</td>
<td>-0.22</td>
<td>0</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-5.0%</td>
<td>-21.0%</td>
<td>-9.0%</td>
<td>5.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746550975_0.png" alt="eps graph" /></p>
<h3>Tracking Liberty Latin America's Stock Performance</h3>
<p>Shares of Liberty Latin America were trading at $5.26 as of May 05. Over the last 52-week period, shares are down 37.98%. Given that these returns are generally negative, long-term shareholders are likely upset going into this earnings release. </p>
<h3>Analysts' Take on Liberty Latin America</h3>
<p>For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Liberty Latin America.</p>
<p>A total of 1 analyst ratings have been received for Liberty Latin America, with the consensus rating being Underperform. The average one-year price target stands at $6.5, suggesting a potential 23.57% upside.</p>
<h3>Comparing Ratings with Competitors</h3>
<p>The analysis below examines the analyst ratings and average 1-year price targets of  and Bandwidth, three significant industry players, providing valuable insights into their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Outperform trajectory for Bandwidth, with an average 1-year price target of $23.0, suggesting a potential 337.26% upside.</li>
</ul>
<h3>Snapshot: Peer Analysis</h3>
<p>The peer analysis summary outlines pivotal metrics for  and Bandwidth, demonstrating their respective standings within the industry and offering valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Liberty Latin America</td>
<td>Underperform</td>
<td>-1.14%</td>
<td>$761.10M</td>
<td>-15.16%</td>
</tr>
<tr>
<td>Bandwidth</td>
<td>Outperform</td>
<td>26.96%</td>
<td>$76.51M</td>
<td>-0.54%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>In comparison to its peers, Liberty Latin America ranks lower in Consensus rating. It also shows negative Revenue Growth, indicating a decline in sales compared to a peer with positive growth. Additionally, its Gross Profit is higher than one peer but lower than another. Lastly, Liberty Latin America has a lower Return on Equity compared to one of its peers.</p>
<h3>All You Need to Know About Liberty Latin America</h3>
<p>Liberty Latin America Ltd is a telecommunications company. It is a provider of video, broadband internet, fixed-line telephony, and mobile services to residential and business customers. The company's reportable segments include C&amp;W Caribbean, Liberty Networks, C&amp;W Panama, VTR, Liberty Puerto Rico and Liberty Costa Rica. The company generates the majority of its revenue from C&amp;W Caribbean, and Liberty Puerto Rico segments.</p>
<h3>Liberty Latin America: A Financial Overview</h3>
<p><strong>Market Capitalization:</strong> With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.</p>
<p><strong>Revenue Growth:</strong> Liberty Latin America's revenue growth over a period of 3 months has faced challenges. As of 31 December, 2024, the company experienced a revenue decline of approximately <strong>-1.14%</strong>. This indicates a decrease in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Communication Services sector.</p>
<p><strong>Net Margin:</strong> Liberty Latin America's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of <strong>-15.47%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Liberty Latin America's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of <strong>-15.16%,</strong> the company may encounter challenges in delivering satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Liberty Latin America's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of <strong>-1.39%,</strong> the company showcases efficient use of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>7.29</strong>, Liberty Latin America adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<p><a href="https://www.benzinga.com/quote/LILA/earnings"><strong>To track all earnings releases for Liberty Latin America visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


LILA

Earnings Preview For Liberty Latin America

<p><strong>SITE Centers</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SITC#NYSE">SITC</a>) is set to give its latest quarterly earnings report on Wednesday, 2025-05-07. Here's what investors need to know before the announcement.</p>
<p>Analysts estimate that SITE Centers will report an <strong>earnings per share</strong> (EPS) of $0.18. </p>
<p>SITE Centers bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Overview of Past Earnings</h3>
<p>The company's EPS missed by $0.07 in the last quarter, leading to a 1.52% increase in the share price on the following day.</p>
<p>Here's a look at SITE Centers's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.23</td>
<td>0.87</td>
<td>0.96</td>
<td></td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.16</td>
<td>0.81</td>
<td>1.08</td>
<td>1.12</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>2.0%</td>
<td>-3.0%</td>
<td>-3.0%</td>
<td>2.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746550947_0.png" alt="eps graph" /></p>
<h3>Stock Performance</h3>
<p>Shares of SITE Centers were trading at $11.88 as of May 05. Over the last 52-week period, shares are down 27.93%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/SITC/earnings"><strong>To track all earnings releases for SITE Centers visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


SITC

A Preview Of SITE Centers's Earnings

<p>Mirum Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MIRM#NASDAQ">MIRM</a>) is gearing up to announce its quarterly earnings on Wednesday, 2025-05-07. Here's a quick overview of what investors should know before the release.</p>
<p>Analysts are estimating that Mirum Pharmaceuticals will report an <strong>earnings per share</strong> (EPS) of $-0.27.</p>
<p>Anticipation surrounds Mirum Pharmaceuticals's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.</p>
<p>New investors should understand that while earnings performance is important, market reactions are often driven by guidance.</p>
<h3>Performance in Previous Earnings</h3>
<p>Last quarter the company missed EPS by $0.24, which was followed by a 7.02% drop in the share price the next day.</p>
<p>Here's a look at Mirum Pharmaceuticals's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.25</td>
<td>-0.45</td>
<td>-0.47</td>
<td>-0.48</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.49</td>
<td>-0.30</td>
<td>-0.52</td>
<td>-0.54</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-7.000000000000001%</td>
<td>4.0%</td>
<td>2.0%</td>
<td>3.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746550932_0.png" alt="eps graph" /></p>
<h3>Tracking Mirum Pharmaceuticals's Stock Performance</h3>
<p>Shares of Mirum Pharmaceuticals were trading at $44.15 as of May 05. Over the last 52-week period, shares are up 65.16%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/MIRM/earnings"><strong>To track all earnings releases for Mirum Pharmaceuticals visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


MIRM

Preview: Mirum Pharmaceuticals's Earnings

Trading Ideas

HOOD

PANW

CNBC Halftime Report Final Trades: Robinhood Markets, Zscaler, Palo Alto Networks, Realty Income

Press Releases

Auddia Inc. to Participate in the 2024 Gaming, Media & Entertainment Virtual Conference, Presented by Maxim Group LLC

Auddia Announces Doubling the Number of Stations in Its faidr Mobile App

Auddia Announces Higher Than Expected Success in User Retention and Shifts Focus to Optimizing Subscription Conversions

Events

Auddia to Present at the Virtual Investor Summit Microcap Event on November 21st

Auddia Announces Acceleration of User Retention Momentum into Q4 in Support of Subscription Revenue Growth in 2025

Auddia Announces Continued Favorable 30-day Retention and the Launch of Commercial Subscriptions

Comments

Auddia

Auddia (AUUD) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO